

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. Patent No. **5,776,456**

Group Art Unit: 1644

Serial No.: **08/ 476,275**

Confirmation No.: 4717

Examiner: R.B. Schwadron

Filed: 7 June 1995

Applicant: Darrell R. ANDERSON *et al.*

For: Therapeutic Application of Chimeric and Radiolabeled Antibodies to Human B
Lymphocyte Restricted Differentiation Antigen for Treatment of B Cell Lymphoma

Mail Stop **Post Issue**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

POWER OF ATTORNEY BY ASSIGNEE AND CHANGE OF CORRESPONDENCE ADDRESS

The assignee of the entire right, title, and interest in U.S. Patent No. 5,776,456 (filed as application serial no. 08/476,275), Biogen Idec Inc., hereby revokes all previous powers of attorney in the above-identified patent and appoints the practitioners associated with

CUSTOMER NUMBER 47553

as its attorneys and agents to prosecute the captioned patent and to transact all business in the U.S. Patent and Trademark Office connected therewith. This appointment extends to the application filed under 35 U.S.C. § 156 to extend the term of the captioned patent.

Direct all correspondence regarding this patent and the application for term extension, except as noted below, to the address associated with **CUSTOMER NUMBER 47553**.

Please note the **new attorney docket number** for this application, **27693-01003**.

The "fee address" for this patent remains unchanged.

Pursuant to 37 C.F.R. § 3.73(b), the undersigned states that Biogen Idec Inc. is the assignee of the entire right, title, and interest in the captioned patent. This patent was granted on a divisional of application serial no. 08/149,099, now U.S. Patent No. 5,736,137. An assignment of the '137 patent by the inventors to IDEC Pharmaceuticals Corp., recorded at Reel 006850/ Frame 0468, has effect as to this patent. M.P.E.P. § 306.

IDEC Pharmaceuticals Corp. now conducts business as Biogen Idec Inc.

The undersigned, whose title is supplied below, is authorized to act on behalf of the assignee.

Respectfully submitted,



Christopher A. Dayton
Associate General Counsel, IP
Biogen Idec Inc.

11/6/95
Date